Partnerre Asset Management reduced its stake in Pfizer Inc. (NYSE:PFE) by 62.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 41,627 shares of the biopharmaceutical company’s stock after selling 69,990 shares during the period. Pfizer comprises approximately 0.7% of Partnerre Asset Management’s portfolio, making the stock its 20th largest position. Partnerre Asset Management’s holdings in Pfizer were worth $1,344,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in PFE. Jennison Associates increased its stake in Pfizer by 108.2% in the third quarter. Jennison Associates now owns 9,550,121 shares of the biopharmaceutical company’s stock valued at $299,969,000 after buying an additional 4,963,367 shares during the last quarter. Eagle Asset Management increased its stake in Pfizer by 100.3% in the third quarter. Eagle Asset Management now owns 7,570,014 shares of the biopharmaceutical company’s stock worth $237,774,000 after buying an additional 3,791,218 shares in the last quarter. Janus Capital Management increased its stake in Pfizer by 35.2% in the third quarter. Janus Capital Management now owns 11,561,514 shares of the biopharmaceutical company’s stock worth $363,157,000 after buying an additional 3,012,704 shares in the last quarter. Verde Servico Internacionais purchased a new stake in Pfizer during the fourth quarter worth about $24,213,000. Finally, J. Goldman & Company increased its stake in Pfizer by 802.0% in the third quarter. J. Goldman & Company now owns 460,000 shares of the biopharmaceutical company’s stock worth $14,449,000 after buying an additional 409,000 shares in the last quarter.

Pfizer Inc. (NYSE:PFE) opened at 30.49 on Friday. The stock’s 50 day moving average price is $31.56 and its 200 day moving average price is $33.11. The company has a market cap of $188.21 billion and a P/E ratio of 22.89. Pfizer Inc. has a 52-week low of $28.47 and a 52-week high of $36.46.

The business also recently announced a quarterly dividend, which will be paid on Wednesday, March 2nd. Investors of record on Friday, February 5th will be issued a dividend of $0.30 per share. This represents a $1.20 annualized dividend and a yield of 3.94%. This is a positive change from Pfizer’s previous quarterly dividend of $0.24. The ex-dividend date of this dividend is Wednesday, February 3rd.

A number of equities research analysts have issued reports on PFE shares. Jefferies Group boosted their price target on Pfizer to $48.00 and gave the company a “buy” rating in a research note on Monday, December 7th. Vetr upgraded Pfizer from a “buy” rating to a “strong-buy” rating and set a $37.47 price target for the company in a research note on Tuesday, October 6th. Cowen and Company upgraded Pfizer from a “market perform” rating to an “outperform” rating and boosted their price target for the company from $25.00 to $43.00 in a research note on Tuesday, October 20th. Zacks Investment Research downgraded Pfizer from a “buy” rating to a “hold” rating in a research note on Monday, January 4th. Finally, Atlantic Securities started coverage on Pfizer in a research note on Friday, December 18th. They set an “overweight” rating and a $39.00 price target for the company. Six equities research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Pfizer has a consensus rating of “Buy” and an average price target of $39.83.

Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its products include Lyrica, the Prevnar family of products, Enbrel, Celebrex, Lipitor, Viagra, Zyvox, Sutent, EpiPen, Toviaz, Tygacil, Rapamune, Xalkori, Inlyta, Norvasc, BeneFIX, Genotropin and Enbrel, among others. It operates in three segments: Global Innovative Pharmaceutical segment (NYSE:PFE), Global Vaccines, Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing, registering and commercializing medications in therapeutic areas, such as inflammation, cardiovascular/metabolic, neuroscience and pain, rare diseases and women’s/men’s health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira, Inc.

12 Month Chart for NYSE:PFE

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.